Xingbin Hu
Overview
Explore the profile of Xingbin Hu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
722
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gu S, Xu J, Liu E, Hou X, An N, Chen Y, et al.
Res Pract Thromb Haemost
. 2025 Mar;
9(1):102681.
PMID: 40027443
Background: The timely administration of platelet transfusions is critical for patient survival, and the clinical demand for platelet transfusions has been steadily increasing. However, platelet storage lesions (PSLs) that develop...
2.
Tian Y, Li X, Chen Y, Hu X, Liu Y, Luo H, et al.
Langmuir
. 2024 Nov;
40(48):25698-25707.
PMID: 39565220
Navigating through soft and highly confined environments is crucial for bacteria moving within living organisms' tissues, yet this topic has been less explored. In our study, we experimentally harnessed the...
3.
Tan Y, Lin K, Zhao Y, Wu Q, Chen D, Wang J, et al.
Theranostics
. 2024 Sep;
14(14):5743-5744.
PMID: 39310096
[This corrects the article DOI: 10.7150/thno.28219.].
4.
Wang F, Wang W, Wu X, Liu Z, Wang Y, Zhang R, et al.
Genes Dis
. 2024 Jun;
11(5):101104.
PMID: 38882017
No abstract available.
5.
Wang W, Chen Y, Chen Y, Liu E, Li J, An N, et al.
Microbiol Spectr
. 2024 Jan;
12(3):e0127923.
PMID: 38289116
Multidrug-resistant strains, especially carbapenem-resistant , have become a rapidly emerging crisis worldwide, greatly limiting current therapeutic options and posing new challenges to infection management. Therefore, it is imperative to develop...
6.
Chen H, Hu X, Wang D, Wang Y, Yu Y, Yao H
Transl Oncol
. 2023 Aug;
37:101738.
PMID: 37597296
Background: This study aimed to comprehensively explore the clinical significance of PIK3CA mutation in human epidermal growth factor receptor 2 (HER2)-positive breast cancer treated with anti-HER2 therapy. Methods: We systematically...
7.
Chen Y, Meng W, Ren G, An N, Zhang J, Liu Z, et al.
Heliyon
. 2023 Jul;
9(7):e18038.
PMID: 37483815
Mesenchymal stem cells (MSCs) are becoming more popular in therapy. Therefore, in-depth studies on mesenchymal stem cells in therapy are urgently needed. However, the difficulty in culturing and propagating MSCs...
8.
Hu X, Ma Z, Xu B, Li S, Yao Z, Liang B, et al.
Cancer Commun (Lond)
. 2023 Jul;
43(8):909-937.
PMID: 37434399
Background: Trastuzumab is a first-line targeted therapy for human epidermal growth factor receptor-2 (HER2)-positive gastric cancer. However, the inevitable occurrence of acquired trastuzumab resistance limits the drug benefit, and there...
9.
Zeng X, Fan H, Kou J, Lu D, Huang F, Meng X, et al.
Front Med (Lausanne)
. 2023 Jul;
10:1167452.
PMID: 37425304
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become the most common coronavirus that causes large-scale infections worldwide. Currently, several studies have shown that the ABO blood group is associated...
10.
Xin J, Zhang H, Yin D, An N, Chen Y, Xu J, et al.
Genes Dis
. 2023 May;
10(2):596-607.
PMID: 37223541
With the development of tyrosine kinase inhibitor (TKI) resistance, finding the novel effective chemotherapeutic agent is of seminal importance for chronic myelogenous leukemia (CML) treatment. This study aims to find...